Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Researchers.
- Curriculum.
- Publications.
- Projects.
- Presentations.
- Advised theses.
Institutions.
Projects.
Publications.
Partners.
Sponsors.
Equipment.
Knowhow.
Fields of Research.

Zach David |

Presentations at scientific and public conferences

Debonnaire, P; Dujardin, K; Verheyen, N; Pouleur, AC; Droogmans, S; Claeys, M; El Haddad, M; Christiaen, E; Zach, D; Buytaert, L; Jacobs, A; Buysschaert, I; Trenson, S; Van Hoeyweghen, R; Tavernier, R AI-enabled cardiac chambers volumetry in non-contrast coronary artery calcium CT scans vs. contrast-enhanced coronary CT angiography scans in the same patients
EUR HEART J. 2024; 45: ehae666206 Doi: 10.1093/eurheartj/ehae666.206 [Poster]
Web of Science FullText FullText_MUG

Schwegel, N; Santner, ; Zach, DK; Hoeller, ; Wallner, M; Muendlein, A; Brandtner, EM; Leiherer, A; Drexel, H; Mader, A; Von Lewinski, D; Ablasser, K; Kolesnik, E; Zirlik, A; Verheyen, N Prognostic value of circulating glypican-4 in patients with chronic heart failure with reduced ejection fraction
EUR HEART J. 2024; 45(S1):ehae666971--ESC Congress; AUG 30-SEP 02, 2024; London, UK. Doi: 10.1093/eurheartj/ehae666.971 [Poster]
Web of Science FullText FullText_MUG

Toferer, C; Schwegel, N; Santner, ; Zach, DK; Hoeller, ; Wallner, M; Gollmer, J; Aziz, F; Von Lewinski, D; Kolesnik, E; Ablasser, K; Zirlik, A; Sourij, H; Verheyen, N Prognostic impact of SGLT2-inhibitor therapy on survival in patients with transthyretin amyloid cardiomyopathy
EUR HEART J. 2024; 45(S1):ehae6662037--ESC Congress; AUG 30-SEP 02, 2024; London, UK. Doi: 10.1093/eurheartj/ehae666.2037 [Poster]
Web of Science FullText FullText_MUG

Winkelbauer, L; Santner, ; Schwegel, N; Hoeller, ; Gollmer, J; Kolesnik, E; Wallner, M; Von Lewinski, D; Zirlik, A; Ablasser, K; Verheyen, N; Zach, D Left atrial reservoir strain differentiates cardiac amyloidosis and hypertrophic cardiomyopathy
EUR HEART J. 2024; 45(S1):ehae666946--ESC Congress; AUG 30-SEP 02, 2024; London, UK. Doi: 10.1093/eurheartj/ehae666.946 [Poster]
Web of Science FullText FullText_MUG

Zach, DK; Batzner, A; Schwegel, N; Santner, ; Hoeller, ; Ablasser, K; Morbach, C; Stoerk, S; Maack, C; Reiter, U; Rainer, PP; Frantz, S; Zirlik, A; Seggewiss, H; Verheyen, N Residual mitral leaflet length independently indicates left ventricular outflow tract obstruction in hypertrophic cardiomyopathy
EUR HEART J. 2024; 45: ehae666098 Doi: 10.1093/eurheartj/ehae666.098 [Poster]
Web of Science FullText FullText_MUG

Lugitsch, J; Hoeller, V; Schwegel, N; Santner, V; Gollmer, J; Kolesnik, E; Lipp, R; Niedrist, T; Rainer, P; Zirlik, A; Ablasser, K; Verheyen, N; Zach, D Interleukin-6 plasma levels predict mortality and heart failure events in cardiac transthyretin amyloidosis
EUR HEART J. 2023; 44: -Annual Meeting of the European-Society-of-Cardiology (ESC); AUG 25-28, 2023; Amsterdam, NETHERLANDS. [Poster]
Web of Science

Lugitsch, J; Holler, V; Schwegel, N; Santner, V; Gollmer, J; Kolesnik, E; Lipp, R; Niedrist, T; Rainer, P; Zirlik, A; Ablasser, K; Verheyen, N; Zach, D Interleukin-6 plasma levels predict mortality and heart failure events in cardiac transthyretin amyloidosis
WIEN KLIN WOCHENSCHR. 2023; 135: S472-S473. [Poster]
Web of Science FullText

Schwegel, N; Riepl, H; Spath, J; Kolesnik, E; Zach, D; Santner, V; Holler, V; Obermayer-Pietsch, B; Schmid, J; Scherr, D; von Lewinski, D; Zirlik, A; Ablasser, K; Verheyen, N Role of Comorbidities in Chronic Heart Failure-a prospective cohort study
WIEN KLIN WOCHENSCHR. 2023; 135: S477-S477.
Web of Science FullText

Zach, D; Schwegel, N; Hoeller, V; Kolesnik, E; Gollmer, J; Reiter, U; Seggewiss, H; Batzner, A; Zirlik, A; Rainer, P; Ablasser, K; Verheyen, N Comparing indices of systemic inflammation and cardiac phenotype between hypertensive and non-hypertensive hypertrophic cardiomyopathy
EUR HEART J. 2023; 44: -Annual Meeting of the European-Society-of-Cardiology (ESC); AUG 25-28, 2023; Amsterdam, NETHERLANDS. [Poster]
Web of Science

Zach, D; Schwegel, N; Holler, V; Kolesnik, E; Gollmer, J; Reiter, U; Seggewiss, H; Batzner, A; Zirlik, A; Rainer, P; Ablasser, K; Verheyen, N Comparing indices of systemic inflammation and cardiac phenotype in hypertensive and non-hypertensive hypertrophic cardiomyopathy
WIEN KLIN WOCHENSCHR. 2023; 135: S475-S476. [Poster]
Web of Science FullText

Grubler, M; Zach, D; Holler, V; Seebacher, HA; Verheyen, N A rare genetic cause of left ventricular hypertrophy and heart failure with preserved ejection fraction
WIEN KLIN WOCHENSCHR. 2022; 134(SUPPL 2):129-129. [Poster]
Web of Science

Verheyen, N; Batzner, A; Zach, D; Gerull, B; Frantz, S; Maack, C; Stork, S; Seggewiss, H; Morbach, C Quantification of systolic anterior motion of the mitral valve to identify left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy
WIEN KLIN WOCHENSCHR. 2022; 134(SUPPL 2): 102-103. [Poster]
Web of Science

Verheyen, N; Batzner, A; Zach, D; Zirlik, A; Gerull, B; Stoerk, S; Maack, C; Seggewiss, H; Morbach, C Quantification of systolic anterior motion of the mitral valve to predict left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy
EUR HEART J. 2022; 43: 158-158.
Web of Science

Verheyen, N; Ungericht, M; Paar, L; Danninger, K; Schneiderbauer-Porod, S; Duca, F; Cherouney, B; Holler, V; Ablasser, K; Zach, D; Kiblbock, D; Frick, M; Bonderman, D; Dierneder, J; Ebner, C; Weber, T; Polzl, G Diagnostic accuracy of amyloid scintigraphy for the histopathological diagnosis of cardiac transthyretin amyloidosis-a retrospective Austrian multicenter study
WIEN KLIN WOCHENSCHR. 2022; 134(SUPPL 2): 89-90. [Poster]
Web of Science

Holler, V; Zach, D; Kolesnik, E; Wallner, M; Fruhwald, F; Rainer, P; Zirlik, A; Verheyen, N Proportions and temporal trends of diseases leading to a hypertrophic cardiomyopathy phenotype. a prospective single-center cohort study
WIEN KLIN WOCHENSCHR. 2021; 133(SUPPL 3):S98-S98. [Onlinepräsentation]
Web of Science

Hoheneder, T; Ablasser, K; Zach, D; Kolesnik, E; Binder, J; Scherr, D; Fruhwald, F; Zirlik, A; von Lewinski, D; Verheyen, N Echocardiographic right ventricular function assessment in patients with chronic heart failure-comparison between TAPSE and myocardial deformation analysis.
WIEN KLIN WOCHENSCHR. 2020; 132: S200-S201. [Poster]
Web of Science FullText

Riepl, H; Wallner, M; Zach, D; Kolesnik, E; Ablasser, K; Zirlik, A; Kreuzer, P; Lueger, A; Verheyen, N Prevalence of heart failure with preserved ejection fraction among patients with decompensated heart failure in an emergency unit.
2. Grazer Herzkreislauftage; SEP 11-13; Graz, AUSTRIA. 2020. [Poster]

Zach, D; Ablasser, K; Kolesnik, E; Fruhwald, F; Pruller, F; Reiter, C; Beham-Schmid, C; Lipp, R; Zirlik, A; Wolfler, A; Verheyen, N Massive cardiac AL amyloidosis in the absence of monoclonal gammopathy.
WIEN KLIN WOCHENSCHR. 2020; 132: S237-S237. [Poster]
Web of Science FullText

Zach, D; Ablasser, K; Kolesnik, E; Fruhwald, F; Pruller, F; Reiter, C; Beham-Schmid, C; Lipp, R; Zirlik, A; Wolfler, A; Verheyen, N The exceptional Case of massive cardiac AL-Amyloidosis with missing monoclonal Gammopathy.
WIEN KLIN WOCHENSCHR. Abstracts 51.Jahrestagung der Österreichischen Gesellschaft für Innere Medizin. 2020; 132(SUPPL 2):73-73.-51.Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; SEP 24-26, 2020; Salzburg, AUSTRIA. [Poster]
Web of Science

Nicolas, V; Seggewiss, H; Ablasser, K; Kolesnik, E; Zach, D; Binder, J; Zirlik, A; Toth, G Alcohol septal ablation in a patient with hypertrophic obstructive cardiomyopathy due to Anderson-Fabry disease
WIEN KLIN WOCHENSCHR. 2019; 131: 292-292. [Poster]
Web of Science

Verheyen, N; Seggewiss, H; Ablasser, A; Kolesnik, E; Zach, D; Binder, J; Zirlik, A; Toth, G Alcohol septal ablation in a patient with hypertrophic obstructive cardiomyopathy due to Anderson-Fabry disease.
https://esc365.escardio.org/Congress/Heart-Failure-2019-6th-World-Congress-on-Acute-Heart-Failure/Oral-Clinical-Case-2/192919-alcohol-septal-ablation-in-a-patient-with-hypertrophic-obstructive-cardiomyopathy-due-to-anderson-fabry-disease#abstract. 2019; -ESC Heart Failure Congress; MAY 25 - 28, 2019; Athen, Greece. [Oral Communication]

Verheyen, NN; Seggewiss, H; Ablasser, K; Kolesnik, E; Zach, D; Binder, J; Zirlik, A; Toth, GG Alcohol septal ablation in a patient with hypertrophic obstructive cardiomyopathy due to Anderson-Fabry disease
EUR J HEART FAIL. Abstracts of the Heart Failure 2019 and the World Congress on Acute Heart Failure, 25–28 May 2019, Megaron Athens International Conference Centre, Greece. 2019; 21(S1):344-344.-Heart Failure 2019 and the World Congress on Acute Heart Failure; MAY 25-28, 2019; Athens, Greece. [Poster]
Web of Science

↑ Top of page / Navigation